Interviews

Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.

Kenny Cole, MD, of Ochsner Health, spoke to the value integrated teams bring to health care and the obstacles that hinder health systems' ability to move toward integrated care approaches.

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month for proteinuria reduction.

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from February as an alternative to more complex and time-consuming regimens in the setting of relapsed/refractory large B-cell lymphoma (R/R LBCL).

Neha Kashalikar, PharmD, director of strategic pharmacy consulting at MassHealth, breaks down the outcome measures often used in pharmacy and medical claims to evaluate the performance of value-based contracts.

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, underscores the importance of ongoing research into outcomes for MA beneficiaries vs fee-for-service (FFS) Medicare beneficiaries.

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center and VERIFY investigator, speaks to the impressive patient-reported outcomes seen thus far.

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.

An expert on the intersection of HIV and menopause, Bridgette J. Picou, LVN, ACLPN, The Well Project, explains the importance of overcoming siloed care for women living with HIV and going through menopause.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, shares how health care leaders are advancing value-based care through improved data strategies, real-world evidence, and AI-driven efficiencies, without losing the human touch.

Adam Colborn, JD, associate vice president for congressional affairs, Academy of Managed Care Pharmacy, highlights key policy updates that are impacting managed care pharmacy.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to support the FDA’s recent approval of iptacopan (Fabhalta; Novartis) in complement 3 glomerulopathy (C3G).

Experts agree that the expansion of telehealth was one of the most significant positive outcomes of the COVID-19 pandemic.

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (AChR+ gMG), explained MINT principal investigator Richard Nowak, MD, MS, Yale School of Medicine.

Attendees of the Academy of Managed Care Pharmacy annual meeting share explain what draws them to the conference year after year.

Giulio Cossu, MD, University of Manchester, discusses barriers to gene therapy research and development.

Clinical approaches to non-Hodgkin lymphoma in younger and older patient groups generally do not differ, according to Andrew Evens, DO, but he emphasized the need for deeper clinical insights into potential biologic differences in younger oncology patients.

Lynae Darbes, PhD, discussed the findings of her study, which found that home-based visits helped to encourage the uptake of HIV testing.

Adolescent and Young Adult Cancer Awareness Week serves as an opportunity to shed light on the special considerations and experiences of younger oncology patient populations.

As new Federal Communications Commission rules take effect April 11, 2025, mPulse CEO Bob Farrell explains how health organizations can stay compliant while building patient trust through transparency and personalized engagement.

Experts highlight groundbreaking research presented at the American College of Cardiology Annual Scientific Session (ACC.25), which emphasized a shift toward more personalized, evidence-based treatment strategies.

Experts agree that telemedicine continues to majorly impact health care post pandemic.

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and Medicaid committees.

Sam Peasah, PhD, MBA, RPh, director of High-Value Health Care Value-Based Pharmacy Initiatives at UPMC Health Plan, shares findings from a study on the cost impact of achieving 80% adherence to newer antidiabetic agents.

Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in reducing cardiovascular death did not significantly differ across baseline bilirubin tertiles.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.

Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).

JC Scott, CEO and president of The Pharmaceutical Care Management Association, discusses the evolving role pharmacy benefit managers (PBMs) play in addressing payer, provider, and patient needs.

Caspian Oliai, MD, MS, medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center, discusses findings from the phase 3 Precision-T trial of Orca-T in acute leukemia and myelodysplastic syndrome (MDS).